An Educational Platform about Current and Future Paradigms of Neuroimaging in the Management of Alzheimer’s Disease

The first disease‐modifying treatment (DMT) for Alzheimer’s disease (AD) has been approved by the U.S. Food and Drug Administration (FDA) in 2021, with potentially more DMTs becoming available in the coming years. Neuroimaging was shown to support clinical decision making in the management of AD and will play a crucial role in determining patient eligibility and monitoring treatment efficacy and adverse events [1]. However, while neuroimaging takes center stage, image acquisition and analysis is rapidly becoming more complex. Training and education are critical for successful implementation of new imaging tools by (neuro)radiologists in daily clinical practice [2].